The clinical efficacy and pathological assessment of neoadjuvant imatinib treatment in patients with primary gastrointestinal stromal tumors
Chunhui Shou, Weili Yang, Xue Zhang, Xiaodong Wang, Qing Zhang, Jiren Yu · 2025
Read The clinical efficacy and pathological assessment of neoadjuvant imatinib treatment in patients with primary gastrointestinal stromal tumors by Chunhui Shou, Weili Yang, Xue Zhang, Xiaodong Wang, Qing Zhang, Jiren Yu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12780651.txt.
Description
Chunhui Shou leads a team on drug care before surgery for gut tumors. Their study from twenty twenty-five deals with stromal tumors of the gut. The drug used before surgery is called imatinib.
The team looked back at folks with large first tumors. Care spanned a long span of years at their center. They set five grades for how much tumor had shrunk. Life span tests sought traits that shape how long folks live. Most patients were men, and tumors shrank a lot. The grades may help judge care results.
Catalog record
| CREATOR | Chunhui Shou, Weili Yang, Xue Zhang, Xiaodong Wang, Qing Zhang, Jiren Yu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |